A simple measurement that can be taken from any routine blood sample is attracting renewed attention as a possible prognostic tool in myelodysplastic syndromes, a group of bone marrow disorders in which blood cell production fails and patients face a persistent risk of progression to acute leukemia. The measurement, known as the immature platelet fraction, or IPF, captures the proportion of newly released, still immature platelets circulating in the blood. Because platelets enter the bloodstream directly from the bone marrow once they detach from megakaryocytes, the fraction of immature forms is widely regarded as a real-time window into thrombopoiesis, the process of platelet generation. A team of hematologists at St. Mary’s Hospital in Kurume, Japan, led by Satoshi Yamasaki, has now put this biomarker to a rigorous test in patients with myelodysplastic syndromes, publishing their findings in the Annals of Hematology.
The rationale behind the study is straightforward. In healthy individuals, the immature platelet fraction typically accounts for only a small percentage of all platelets, and it rises when the marrow is under pressure to replenish circulating platelets, for example after chemotherapy or in immune thrombocytopenia. In myelodysplastic syndromes, however, the marrow is intrinsically dysfunctional, and the relationship between platelet production and clinical outcome is far less predictable. If a high IPF reflects compensatory but ineffective platelet output, or if it signals biologically more aggressive disease, then the measurement might help clinicians identify patients at higher risk of leukemic transformation or death. Conversely, if the IPF adds nothing beyond established scoring systems, its clinical use would need to be reconsidered.
To address these questions, the researchers designed a two-part investigation. The retrospective arm drew on 364 patients with myelodysplastic syndromes whose baseline IPF values and clinical courses were available from hospital records. The prospective arm enrolled 46 patients under a registered observational protocol, identified as UMIN000057807, in whom the investigators followed outcomes forward in time with standardized assessments. The primary endpoint in both analyses was leukemia-free survival, a composite measure defined as the time until either transformation to acute myeloid leukemia or death from any cause. Secondary endpoints included overall survival and, among patients treated with the hypomethylating agent azacitidine, the rate of hematological improvement.
The retrospective results provided the first hint that the IPF might carry prognostic weight. Using a cutoff of 6.8 percent, the researchers divided the 364 patients into low and high IPF groups and found that 50 leukemia-free survival events occurred during follow-up. Patients whose baseline IPF exceeded 6.8 percent experienced significantly shorter leukemia-free survival and shorter overall survival in unadjusted analyses, with log-rank p values of 0.033 and 0.022 respectively. In a univariable model, a high IPF was associated with a hazard ratio of 1.79 for leukemia-free survival, meaning a roughly 79 percent increase in the risk of leukemic transformation or death, with a 95 percent confidence interval spanning 1.02 to 3.16.
Prognostic research, however, demands caution before celebrating any single variable, and the adjusted analyses told a more nuanced story. When the investigators controlled for age, platelet count, and the Revised International Prognostic Scoring System, a widely used risk stratification tool in myelodysplastic syndromes, the association retained a similar magnitude but lost statistical significance. The adjusted hazard ratio for leukemia-free survival was 2.02, with a 95 percent confidence interval of 0.98 to 4.18 and a p value of 0.057, sitting just at the threshold of conventional significance. The point estimate actually grew larger after adjustment, suggesting the IPF may capture information beyond standard scores, but the wide confidence interval reflects the limited number of events and leaves the conclusion uncertain. The discriminatory performance of the continuous IPF was likewise modest, with a two-year time-dependent area under the curve of 0.638 and a 95 percent confidence interval of 0.561 to 0.715, well short of the near-perfect separation clinicians would want from a standalone biomarker.
The study also probed the biological meaning of the IPF by comparing it with direct examination of the bone marrow. The continuous IPF value showed a moderate correlation with the bone marrow megakaryocyte count, quantified by a Spearman’s rank correlation coefficient of 0.50 with a p value below 0.001. Interestingly, however, the median megakaryocyte counts were identical across the high and low IPF groups, indicating that the correlation, while statistically robust, did not translate into a simple categorical distinction. This pattern suggests that the IPF reflects not merely how many megakaryocytes populate the marrow but how productively those cells release platelets, a functional dimension that conventional morphology may miss in dysplastic marrow.
The prospective cohort was intended to test these retrospective signals under more controlled conditions, and here the picture shifted. Among the 46 prospectively enrolled patients, overall survival and leukemia-free survival did not differ between those with an IPF at or below 6.8 percent and those above the threshold, with log-rank p values of 0.929 and 0.402 respectively. The explanation lies partly in the numbers: only three deaths and four leukemia-free survival events occurred in this small cohort, far too few to detect anything but a dramatic effect. Exploratory prospective studies of this size are inherently underpowered, and the absence of a difference should be read as inconclusive rather than as evidence that the IPF is prognostically irrelevant.
The azacitidine analysis added a therapeutic dimension to the investigation. Azacitidine, a hypomethylating agent, is a mainstay of treatment for higher-risk myelodysplastic syndromes, yet responses vary considerably between patients, and clinicians lack reliable predictors of who will benefit. Among response-evaluable patients treated with azacitidine, hematological improvement occurred in 4 of 14 patients, or 28.6 percent, in the high IPF group, compared with 5 of 8 patients, or 62.5 percent, in the low IPF group. The difference is striking in relative terms but did not reach statistical significance, with a p value of 0.187, and the tiny denominators make any interpretation speculative. Still, the direction of the effect raises the possibility that a high IPF, perhaps signaling more severely disordered thrombopoiesis, could be associated with reduced responsiveness to azacitidine, a hypothesis that only adequately powered trials can confirm or refute.
The authors are careful to frame the IPF as an investigational biomarker rather than a validated clinical tool, and their caution is warranted. The measurement itself is attractive: it is generated automatically by modern hematology analyzers using fluorescent dyes or equivalent technologies that stain RNA-rich reticulated platelets, requires no additional blood draw, and delivers results within the routine complete blood count workflow. Yet the present study demonstrates the classic challenges of biomarker research in rare malignancies. The retrospective signal was genuine but weakened after adjustment for established prognostic factors, the prospective cohort was too small to confirm or refute it, and the discriminatory capacity of the marker was modest at best. The investigators explicitly call for validation in adequately powered multicenter cohorts, which would allow event numbers sufficient for stable adjusted estimates and subgroup analyses across disease risk categories.
For patients and clinicians, the takeaway is one of tempered interest rather than immediate practice change. The immature platelet fraction is not yet ready to join the Revised International Prognostic Scoring System or molecular risk panels in guiding treatment intensity or transplant decisions. What the study does establish is a credible biological and statistical foundation for continued investigation: a plausible mechanism linking platelet turnover to disease behavior, a reproducible retrospective association, and a prospectively collected dataset that can inform the design of larger studies. As flow cytometry-derived and analyzer-derived markers of hematopoietic stress accumulate, the IPF may ultimately find its place alongside other measures in a composite prognostic model. Until such validation arrives, the 6.8 percent threshold remains a research cutoff, not a clinical decision point, and patients with myelodysplastic syndromes will continue to be risk-stratified by the established tools that decades of evidence have validated.
Subject of Research: Prognostic value of the immature platelet fraction in myelodysplastic syndromes
Article Title: The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment
Article References: Yamasaki, S., Hashiguchi, M., Yoshida-Sakai, N., Jojima, H., Osaki, K., Okamura, T., & Imamura, Y. (2026). The immature platelet fraction in myelodysplastic syndromes: retrospective associations and exploratory prospective cohort assessment. Annals of Hematology. https://doi.org/10.1007/s00277-026-07270-z
Image Credits: AI Generated
DOI: 10.1007/s00277-026-07270-z
Keywords: myelodysplastic syndromes, immature platelet fraction, biomarker, prognosis, azacitidine, acute myeloid leukemia, leukemia-free survival, thrombopoiesis, megakaryocytes, hematology, prospective cohort study, Revised International Prognostic Scoring System
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (October 2, 2026). Immature Platelet Fraction Shows Mixed Prognostic Value in Myelodysplastic Syndromes. Scienmag. https://scienmag.com/immature-platelet-fraction-shows-mixed-prognostic-value-in-myelodysplastic-syndromes/
Nathaniel Bowman. “Immature Platelet Fraction Shows Mixed Prognostic Value in Myelodysplastic Syndromes.” Scienmag, 2 October 2026, https://scienmag.com/immature-platelet-fraction-shows-mixed-prognostic-value-in-myelodysplastic-syndromes/. Accessed 2 October 2026.
Nathaniel Bowman. “Immature Platelet Fraction Shows Mixed Prognostic Value in Myelodysplastic Syndromes.” Scienmag. October 2, 2026. https://scienmag.com/immature-platelet-fraction-shows-mixed-prognostic-value-in-myelodysplastic-syndromes/
Copy citation Download RIS
Tags: acute myeloid leukemiaazacitidinebiomarkerblood sample analysis for MDS prognosisbone marrow failure biomarkershematologyhematology biomarker research in bone marrow disordersimmature platelet fractionimmature platelet fraction prognostic valueimmature platelet measurement clinical utilityimmature platelets and leukemia riskleukemia-free survivalmegakaryocytesmyelodysplastic syndromesmyelodysplastic syndromes blood disorderplatelet dynamics in myelodysplastic syndromesplatelet production assessment in hematologyprognosisprospective cohort studyreal-time thrombopoiesis indicatorRevised International Prognostic Scoring Systemroutine blood test prognostic toolsthrombopoiesisthrombopoiesis monitoring in MDS
